VolitionRX Ltd (VNRX) Scheduled to Post Earnings on Friday
VolitionRX Ltd (NYSEMKT:VNRX) is set to release its earnings data before the market opens on Friday, November 10th. Analysts expect VolitionRX to post earnings of ($0.15) per share for the quarter.
Separately, HC Wainwright set a $10.00 target price on VolitionRX and gave the stock a “buy” rating in a report on Friday, August 11th.
VolitionRX Company Profile
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.
Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.